Skip to main content
NCBI home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;95(6):475–480. doi: 10.1111/j.1349-7006.2004.tb03235.x

Gene mutations and altered gene expression in azoxymethane‐induced colon carcinogenesis in rodents

Mami Takahashi 1,✉, Keiji Wakabayashi 1
PMCID: PMC11158569  PMID: 15182426

Abstract

Studies of colon carcinogenesis in animal models are very useful to elucidate mechanisms and provide pointers to potential prevention approaches in the human situation. In the rat colon carcinogenesis model induced by azoxymethane (AOM), we have documented frequent mutations of specific genes. K‐ras mutations at codon 12 were found to be frequent in hyperplastic aberrant crypt foci (ACF) and large adenocarcinomas. In addition, mutations of the β‐catenin gene in its GSK‐3β phosphorylation consensus motif could also be identified in many adenomas and adenocarcinomas, and altered cellular localization of p‐catenin protein was observed in all of the dysplastic ACF, adenomas and adenocarcinomas examined, indicating that activation of Wnt signaling by accumulation of β‐catenin is a major mechanism in the AOM‐induced colon carcinogenesis model. Frequent gene mutations of β‐catenin and altered cellular localization of the protein are also features of AOM‐induced colon tumors in mice. Expression of enzymes associated with inflammation, such as inducible nitric oxide synthase (INOS) and the inducible type of cyclooxyge‐nase (COX), COX‐2, is increased in AOM‐induced rat colon carcinogenesis, and overproduction of nitric oxide (NO) and prostaglandins is considered to be involved in colon tumor development. We have demonstrated that increased expression of INOS is an early and important event occurring in step with β‐catenin alteration in rat colon carcinogenesis. Activation of K‐ras was also found to be involved in up‐regulation of INOS in the presence of inflammatory stimuli. In addition, expression levels of prostaglandin E2 (PGE2) receptors may be altered in colon cancers. For example, the EP, and EP2 subtypes have been shown to be up‐regulated and EP3 down‐regulated in AOM‐induced colon cancers in rats and mice. EP, and EP4 appear to be involved in ACF formation, while alteration in EP2 and EP3 is considered to contribute to later steps in colon carcinogenesis. Increased expression of some other gene products, such as the targets of Wnt/β‐catenin signaling, have also been reported. The further accumulation of data with this chemically‐induced animal colon carcinogenesis model should provide useful information for understanding colorectal neoplasia in man.

Abbreviations:

AOM

azoxymethane

INOS

inducible nitric oxide synthase

COX

cyclooxygenase

NO

nitric oxide

ACF

aberrant crypt foci

PGE2

prostaglandin E2

MNU

methylnitrosourea

PhIP

2‐amino‐1‐methyl‐6‐phenylimidazo[4,5‐b]pyridine

SSCP

single strand conformation polymorphism

IL‐1β

interleukin‐1β

LPS

lipopolysaccharide

References

  • 1. Boone CW, Steele VE, Kelloff GJ. Screening for chemopreventive (anticar‐cinogenic) compounds in rodents. Mutat Res 1992; 267: 251–5. [DOI] [PubMed] [Google Scholar]
  • 2. Olivo S, Wargovich MJ. Inhibition of aberrant crypt foci by chemopreventive agents. In Vivo 1998; 12: 159–66. [PubMed] [Google Scholar]
  • 3. Hirose Y, Kuno T, Yamada Y, Sakata K, Katayama M, Yoshida K, Qiao Z, Hata K, Yoshimi N, Mori H. Azoxymethane‐induced beta‐catenin‐accumulated crypts in colonic mucosa of rodents as an intermediate biomarker for colon carcinogenesis. Carcinogenesis 2003; 24: 107–11. [DOI] [PubMed] [Google Scholar]
  • 4. Carderni G, Femia, AP , Giannini A, Favuzza A, Luceri C, Salvadori M, Dolara P. Identification of mucin‐depleted foci in the unsectioned colon of azoxymethane‐treated rats: correlation with carcinogenesis. Cancer Res 2003; 63: 2388–92. [PubMed] [Google Scholar]
  • 5. Femia AP, Dolara P, Caderni G. Mucin‐depleted foci (MDF) in the colon of rats treated with azoxymethane (AOM) are useful biomarkers for colon carcinogenesis. Carcinogenesis 2004; 25: 277–81. [DOI] [PubMed] [Google Scholar]
  • 6. Ichii S, Takeda S, Horii A, Nakatsuru S, Miyoshi Y, Emi M, Fujiwara Y, Koyama K, Furuyama J, Utsunomiya J, Nakamura Y. Detailed analysis of genetic alterations in colorectal tumors from patients with and without familial adenomatous polyposis (FAP). Oncogene 1993; 8: 2399–405. [PubMed] [Google Scholar]
  • 7. Miyaki M, Konishi M, Kikuchi‐Yanoshita R, Enomoto M, Igari T, Tanaka K, Muraoka M, Takahashi H, Amada Y, Fukayama M, Maeda Y, Iwama T, Mishima Y, Mori T, Koike M. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res 1994; 54: 3011–20. [PubMed] [Google Scholar]
  • 8. Konishi M, Kikuchi‐Yanoshita R, Tanaka K, Muraoka M, Onda A, Okumura Y, Kishi N, Iwama T, Mori T, Koike M, Ushio K, Chiba M, Nomizu S, Konishi F, Utsunomiya J, Miyaki M. Molecular nature of colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and sporadic colon cancer. Gastroenterology 1996; 111: 307–17. [DOI] [PubMed] [Google Scholar]
  • 9. Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, Kinzler KW. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994; 54: 5523–6. [PubMed] [Google Scholar]
  • 10. Smith AJ, Stern HS, Penner M, Hay K, Mitri A, Bapat BV, Gallinger S. Somatic APC and K‐ras codon 12 mutations in aberrant crypt foci from human colons. Cancer Res 1994; 54: 5527–30. [PubMed] [Google Scholar]
  • 11. Yamashita N, Minamoto T, Ochiai A, Onda M, Esumi H. Frequent and characteristic K‐ras activation and absence of p53 protein accumulation in aberrant crypt foci of the colon. Gastroenterology 1995; 108: 434–40. [DOI] [PubMed] [Google Scholar]
  • 12. Otori K, Konishi M, Sugiyama K, Hasebe T, Shimoda T, Kikuchi‐Yanoshita R, Mukai K, Fukushima S, Miyaki M, Esumi H. Infrequent somatic mutation of the adenomatous polyposis coli gene in aberrant crypt foci of human colon tissue. Cancer 1998; 83: 896–900. [DOI] [PubMed] [Google Scholar]
  • 13. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–67. [DOI] [PubMed] [Google Scholar]
  • 14. Rubinfeld B, Souza B, Albert I, Müller O, Chamberlain SH, Masiarz FR, Munemitsu S, Polakis P. Association of the APC gene product with β‐cate‐nin. Science 1993; 262: 1731–4. [DOI] [PubMed] [Google Scholar]
  • 15. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intra‐cellular β‐catenin levels by the adenomatous polyposis coli (APC) tumor‐suppressor protein. Proc Natl Acad Sci USA 1995; 92: 3046–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis‐inducing activity, stability, and subcellular distribution of β‐catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996; 10: 1443–54. [DOI] [PubMed] [Google Scholar]
  • 17. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of β‐catenin‐Tcf signaling in colon cancer by mutations in β‐catenin or APC. Science 1997; 275: 1787–90. [DOI] [PubMed] [Google Scholar]
  • 18. Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/β‐catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58:1130–4. [PubMed] [Google Scholar]
  • 19. Erdman SH, Wu HD, Hixson LJ, Ahnen DJ, Gerner EW. Assessment of mutations in Ki‐ras and p53 in colon cancers from azoxymethane‐ and dimethylhydrazine‐treated rats. Mol Carcinog 1997; 19: 137–44. [DOI] [PubMed] [Google Scholar]
  • 20. Caderni G, Filippo D, Luceri C, Fazi M, Dolara P, Bazzicalupo M. Ape mutations in aberrant crypt foci and colonic tumors induced by azoxymethane in rats. Proc Am. Assoc Cancer Res 1997; 38: 467 (3122). [Google Scholar]
  • 21. Matsumoto K, Iwase T, Hirono I, Nishida Y, Iwahori Y, Hori T, Asamoto M, Takasuka N, Kim DJ, Ushijima T, Nagao M, Tsuda H. Demonstration of ras and p53 gene mutations in carcinomas in the forestomach and intestine and soft tissue sarcomas induced by N‐methyl‐N‐nitrosourea in the rat. Jpn J Cancer Res 1997; 88: 129–36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Kakiuchi H, Watanabe M, Ushijima T, Toyota M, Imai K, Weisburger JH, Sugimura T, Nagao M. Specific 5“‐GGGA‐3′→5′‐GGA‐3′ mutation of the Apc gene in rat colon tumors induced by 2‐amino‐l‐methy1‐6‐phenylimi‐dazo[4,5‐b]pyridine. Proc Natl Acad Sci USA 1995; 92: 910–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Kakiuchi H, Ushijima T, Ochiai M, Imai K, Ito N, Yachi A, Sugimura T, Nagao M. Rare frequency of activation of the Ki‐ras gene in rat colon tumors induced by heterocyclic amines: possible alternative mechanisms of human colon carcinogenesis. Mol Carcinog 1993; 8: 44–8. [DOI] [PubMed] [Google Scholar]
  • 24. Stopera SA, Murphy LC, Bird RP. Evidence for a ras gene mutation in azoxymethane‐induced colonic aberrant crypts in Sprague‐Dawley rats: earliest recognizable precursor lesions of experimental colon cancer. Carcinogenesis 1992; 13: 2081–5. [DOI] [PubMed] [Google Scholar]
  • 25. Vivona AA, Shpitz B, Medline A, Bruce WR, Ward MA, Stern HS, Gallinger G. K‐ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane‐induced colon carcinogenesis. Carcinogenesis 1993; 14: 1777–81. [DOI] [PubMed] [Google Scholar]
  • 26. Fiala ES. Investigations into the metabolism and mode of action of the colon carcinogens 1,2‐dimethylhydrazine and azoxymethane. Cancer 1977; 40: 2436–45. [DOI] [PubMed] [Google Scholar]
  • 27. Rogers KJ, Pegg AE. Formation of O6‐methylguanine by alkylation of rat liver, colon, and kidney DNA following administration of 1,2‐dimethylhydrazine. Cancer Res 1977; 37: 4082–7. [PubMed] [Google Scholar]
  • 28. Takahashi M, Fukuda K, Sugimura T, Wakabayashi K. β‐Catenin is frequently mutated and demonstrates altered cellular location in azoxymethane‐induced rat colon tumors. Cancer Res 1998; 58: 42–6. [PubMed] [Google Scholar]
  • 29. Takahashi M, Mutoh M, Kawamori T, Sugimura T, Wakabayashi K. Altered expression of β‐catenin, inducible nitric oxide synthase and cyclooxygenase‐2 in azoxymethane‐induced rat colon carcinogenesis. Carcinogenesis 2000; 21: 1319–27. [PubMed] [Google Scholar]
  • 30. Dashwood RH, Suzui M, Nakagama H, Sugimura T, Nagao M. High frequency of β‐catenin (Ctnnbl) mutations in the colon tumors induced by two heterocyclic amines in the F344 rat. Cancer Res 1998; 58: 1127–9. [PubMed] [Google Scholar]
  • 31. Singh J, Kulkarni N, Kelloff G, Reddy BS. Modulation of azoxymethane‐induced mutational activation of ras protooncogenes by chemopreventive agents in colon carcinogenesis. Carcinogenesis 1994; 15: 1317–23. [DOI] [PubMed] [Google Scholar]
  • 32. Takahashi M, Nakatsugi S, Sugimura T, Wakabayashi K. Frequent mutations of the β‐catenin gene in mouse tumors induced by azoxymethane. Carcinogenesis 2000; 21: 1117–20. [PubMed] [Google Scholar]
  • 33. Maltzman T, Whittington J, Driggers L, Stephens J, Ahnen D. AOM‐induced mouse colon tumors do not express full‐length APC protein. Carcinogenesis 1997; 18, 2435–9. [DOI] [PubMed] [Google Scholar]
  • 34. Jackson PE, Cooper DP, O'Connor PJ, Povey AC. The relationship between 1,2‐dimethylhydrazine dose and the induction of colon tumors: tumor development in female SWR mice does not require a K‐ras mutational event. Carcinogenesis 1999; 20: 509–13. [DOI] [PubMed] [Google Scholar]
  • 35. Ambs S, Merriam WG, Bennett WP, Felley‐Bosco E, Ogunfusika MO, Oser SM, Klein S, Shields PG, Billiar TR, Harris CC. Frequent nitric oxide synthase‐2 expression in human colon adenomas: implication for tumor angio‐genesis and colon cancer progression. Cancer Res 1998; 58: 334–41. [PubMed] [Google Scholar]
  • 36. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up‐regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–8. [DOI] [PubMed] [Google Scholar]
  • 37. Takahashi M, Fukuda K, Ohata T, Sugimura T, Wakabayashi K. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res 1997; 57: 1233–7. [PubMed] [Google Scholar]
  • 38. Jenkins DC, Charles IG, Baylis SA, Lelchuk R, Radomski MW, Moncada S. Human colon cancer cell lines show a diverse pattern of nitric oxide synthase gene expression and nitric oxide generation. BrJ Cancer 1994; 70: 847–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Takahashi M, Mutoh M, Shoji Y, Kamanaka K, Naka M, Maruyama T, Sugimura T, Wakabayashi K. Transfection of K‐rasAsp12 cDNA markedly elevates IL‐1β and lipopolysaccharide‐mediated inducible nitric oxide synthase expression in rat intestinal epithelial cells. Oncogene 2003; 22: 7667–76. [DOI] [PubMed] [Google Scholar]
  • 40. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493–501. [DOI] [PubMed] [Google Scholar]
  • 41. DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD. G1, delay in cells overexpressing prostaglandin endoperoxide synthase‐2. Cancer Res 1996; 56: 733–7. [PubMed] [Google Scholar]
  • 42. Tsujii M, Kawano S, Tsujii S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705–16. [DOI] [PubMed] [Google Scholar]
  • 43. Prescott SM, White RL. Self‐promotion? Intimate connections between APC and prostaglandin H synthese‐2. Cell 1996; 87: 783–6. [DOI] [PubMed] [Google Scholar]
  • 44. Howe LR, Subbaramaiah K, Chung WJ, Dannenberg AJ, Brown AMC. Transcriptional activation of cyclooxygenase‐2 in Wnt‐1‐transformed mouse mammary epithelial cells. Cancer Res 1999; 59: 1572–7. [PubMed] [Google Scholar]
  • 45. Mei JM, Hord NG, Winterstein DF, Donald SP, Phang JM. Differential expression of prostaglandin endoperoxide H synthase‐2 and formation of activated β‐catenin‐LEF‐1 transcription complex in mouse colonic epithelial cells contrasting in Apc. Carcinogenesis 1999; 20: 737–40. [DOI] [PubMed] [Google Scholar]
  • 46. Bissonnette M, Khare S, von Lintig FC, Wali RK, Nguyen L, Zhang Y, Hart J, Skarosi S, Varki N, Boss GR, Brasitus TA. Mutational and nonmutational activation of p21ras in rat colonic azoxymethane‐induced tumors: effects on mitogen‐activated protein kinase, cyclooxygenase‐2, and cyclin Dl. Cancer Res 2000; 60: 4602–9. [PubMed] [Google Scholar]
  • 47. Salvemini D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993; 90:7240–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Corbett JA, Kwon G, Turk J, McDaniel ML. IL‐lβ induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans:activation of cyclooxygenase by nitric oxide. Biochemistry 1993; 32: 13767–70. [DOI] [PubMed] [Google Scholar]
  • 49. Salvemini D, Seibert K, Masferrer JL, Misko TP, Currie MG, Needleman P. Endogenous nitric oxide enhances prostaglandin production in a model of renal inflammation. J Clin Invest 1994; 93: 1940–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Landino LM, Crews BC, Timmons MD, Morrow JD, Marnett LJ. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci USA 1996; 93: 15069–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518–23. [PubMed] [Google Scholar]
  • 52. Minoura T, Takata T, Sakaguchi M, Takada H, Yamamura M, Hioki K, Yamamoto M. Effect of dietary eicosapentaenoic acid on azoxymethane‐induced colon Carcinogenesis in rats. Cancer Res 1988; 48: 4790–4. [PubMed] [Google Scholar]
  • 53. Kawamori T, Uchiya N, Sugimura T, Wakabayashi K. Enhancement of colon Carcinogenesis by prostaglandin E2 administration. Carcinogenesis 2003; 24: 985–90. [DOI] [PubMed] [Google Scholar]
  • 54. Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Narumiya S, Sugimura T, Wakabayashi K. Role of the prostaglandin E receptor subtype EP1, in colon Carcinogenesis. Cancer Res 1999; 59: 5093–6. [PubMed] [Google Scholar]
  • 55. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Narumiya S, Sugimura T, Wakabayashi K. Involvement of prostaglandin E receptor subtype EP4 in colon Carcinogenesis. Cancer Res 2002; 62: 28–32. [PubMed] [Google Scholar]
  • 56. Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T, Sugimoto Y, Negishi M, Narumiya S, Sugimura T, Wakabayashi K. Down‐regulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 2004; in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, Oshima M, Taketo MM. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice. Nat Med 2001; 7: 1048–51. [DOI] [PubMed] [Google Scholar]
  • 58. Tetsu O, McCormick F. Beta‐catenin regulates expression of cyclin Dl in colon carcinoma cells. Nature 1999; 398: 422–6. [DOI] [PubMed] [Google Scholar]
  • 59. Utsunomiya T, Doki Y, Takemoto H, Shiozaki H, Yano M, Sekimoto M, Tamura S, Yasuda T, Fujiwara Y, Monden M. Correlation of beta‐catenin and cyclin Dl expression in colon cancers. Oncology 2001; 61: 226–33. [DOI] [PubMed] [Google Scholar]
  • 60. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c‐MYC as a target of the APC pathway. Science 1998; 281: 1509–12. [DOI] [PubMed] [Google Scholar]
  • 61. Kishimoto Y, Morisawa T, Hosoda A, Shiota G, Kawasaki H, Hasegawa J. Molecular changes in the early stage of colon Carcinogenesis in rats treated with azoxymethane. J Exp Clin Cancer Res 2002; 21: 203–11. [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES